226 related articles for article (PubMed ID: 23561044)
1. Microbicide clinical trial adherence: insights for introduction.
Woodsong C; MacQueen K; Amico KR; Friedland B; Gafos M; Mansoor L; Tolley E; McCormack S
J Int AIDS Soc; 2013 Apr; 16(1):18505. PubMed ID: 23561044
[TBL] [Abstract][Full Text] [Related]
2. Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.
Doggett EG; Lanham M; Wilcher R; Gafos M; Karim QA; Heise L
J Int AIDS Soc; 2015; 18(1):20536. PubMed ID: 26700845
[TBL] [Abstract][Full Text] [Related]
3. Methodological lessons from clinical trials and the future of microbicide research.
van der Straten A; Montgomery ET; Hartmann M; Minnis A
Curr HIV/AIDS Rep; 2013 Mar; 10(1):89-102. PubMed ID: 23184582
[TBL] [Abstract][Full Text] [Related]
4. Women design their own vaginal microbicide trial: Suggestions on how to improve adherence from former participants of HIV prevention trials.
Miller L; Morar N; Kapiga S; Ramjee G; Hayes R
PLoS One; 2021; 16(1):e0244652. PubMed ID: 33411782
[TBL] [Abstract][Full Text] [Related]
5. Heterosexual anal intercourse has the potential to cause a significant loss of power in vaginal microbicide effectiveness studies.
McGowan I; Taylor DJ
Sex Transm Dis; 2010 Jun; 37(6):361-4. PubMed ID: 20514687
[TBL] [Abstract][Full Text] [Related]
6. Learning from the private sector: towards a keener understanding of the end-user for microbicide introduction planning.
Lin AH; Breger TL; Barnhart M; Kim A; Vangsgaard C; Harris E
J Int AIDS Soc; 2014; 17(3 Suppl 2):19162. PubMed ID: 25224619
[TBL] [Abstract][Full Text] [Related]
7. Toward an information-motivation-behavioral skills model of microbicide adherence in clinical trials.
Ferrer RA; Morrow KM; Fisher WA; Fisher JD
AIDS Care; 2010 Aug; 22(8):997-1005. PubMed ID: 20552466
[TBL] [Abstract][Full Text] [Related]
8. Engaging male partners in women's microbicide use: evidence from clinical trials and implications for future research and microbicide introduction.
Lanham M; Wilcher R; Montgomery ET; Pool R; Schuler S; Lenzi R; Friedland B
J Int AIDS Soc; 2014; 17(3 Suppl 2):19159. PubMed ID: 25224618
[TBL] [Abstract][Full Text] [Related]
9. Hidden heterogeneity: Uncovering patterns of adherence in microbicide trials for HIV prevention.
Miller L; Prieto Merino D; Baisley K; Hayes R
PLoS One; 2022; 17(5):e0267011. PubMed ID: 35551324
[TBL] [Abstract][Full Text] [Related]
10. Adherence and its measurement in phase 2/3 microbicide trials.
Tolley EE; Harrison PF; Goetghebeur E; Morrow K; Pool R; Taylor D; Tillman SN; van der Straten A
AIDS Behav; 2010 Oct; 14(5):1124-36. PubMed ID: 19924525
[TBL] [Abstract][Full Text] [Related]
11. Sharing Objective Measures of Adherence to a Vaginal Microbicide Promotes Candor About Actual Use and Bolsters Motivation to Prevent HIV.
Kutner BA; Giguere R; Lentz C; Kajura-Manyindo C; Dolezal C; Butheliezi S; Gwande M; Nampiira S; Ndlovu T; Mvinjelwa P; Mwenda W; Balán IC
AIDS Behav; 2021 Mar; 25(3):721-731. PubMed ID: 32920652
[TBL] [Abstract][Full Text] [Related]
12. The last decade of microbicide clinical trials in Africa: from hypothesis to facts.
Ramjee G; Kamali A; McCormack S
AIDS; 2010 Oct; 24 Suppl 4():S40-9. PubMed ID: 21042052
[TBL] [Abstract][Full Text] [Related]
13. Clinical development of microbicides for the prevention of HIV infection.
D'Cruz OJ; Uckun FM
Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
[TBL] [Abstract][Full Text] [Related]
14. Dyeing to know: the use of vaginal applicator staining and other techniques to assess adherence to product use in microbicide trials.
Mauck CK; Schwartz JL
Sex Transm Dis; 2012 Sep; 39(9):713-5. PubMed ID: 22902668
[No Abstract] [Full Text] [Related]
15. State of the science of adherence in pre-exposure prophylaxis and microbicide trials.
Muchomba FM; Gearing RE; Simoni JM; El-Bassel N
J Acquir Immune Defic Syndr; 2012 Dec; 61(4):490-8. PubMed ID: 22932322
[TBL] [Abstract][Full Text] [Related]
16. To tell or not to tell: male partner engagement in a Phase 3 microbicide efficacy trial in South Africa.
Kelly CA; Friedland BA; Morar NS; Katzen LL; Ramjee G; Mokgatle MM; Ahmed K
Cult Health Sex; 2015; 17(8):1004-20. PubMed ID: 25913101
[TBL] [Abstract][Full Text] [Related]
17. Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States.
Montgomery ET; Noguchi LM; Dai JY; Pan J; Biggio J; Hendrix C; Isaacs K; Watts DH; Schwartz JL; Piper J; Beigi R
AIDS Behav; 2018 Feb; 22(2):402-411. PubMed ID: 28550377
[TBL] [Abstract][Full Text] [Related]
18. How informed is consent in vulnerable populations? Experience using a continuous consent process during the MDP301 vaginal microbicide trial in Mwanza, Tanzania.
Vallely A; Lees S; Shagi C; Kasindi S; Soteli S; Kavit N; Vallely L; McCormack S; Pool R; Hayes RJ;
BMC Med Ethics; 2010 Jun; 11():10. PubMed ID: 20540803
[TBL] [Abstract][Full Text] [Related]
19. The meaning of adherence when behavioral risk patterns vary: obscured use- and method-effectiveness in HIV-prevention trials.
de Bruin M; Viechtbauer W
PLoS One; 2012; 7(8):e44029. PubMed ID: 22970107
[TBL] [Abstract][Full Text] [Related]
20. Community and research staff collaboration for development of materials to inform microbicide study participants in Africa.
Woodsong C; Mutsambi JM; Ntshele S; Modikoe P
J Int AIDS Soc; 2014; 17(3 Suppl 2):19156. PubMed ID: 25224615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
